Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.36 |
| ▸ | PDE4A | P27815 | 6/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4665000 | 0.98 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4CATM | |
| SCHEMBL4664353 | 0.90 | KAT2B (0.34) | PDE4DPDE4APDE4BPDE4CATM | |
| Hydrochloric Acid SCHEMBL4668002 | 0.89 | KAT2B (0.33) | PDE4DPDE4APDE4BPDE4CATM | |
| SCHEMBL22413581 | 0.85 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4CATM | |
| Trifluoroacetic Acid SCHEMBL4666342 | 0.82 | SYK (0.30) | — | |
| SCHEMBL6840506 | 0.81 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13617237 | 0.81 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10072446 | 0.76 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13563616 | 0.75 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL22356126 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395551-B1 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | ELAN PHARM INC (US) | 2008-05-21 | — | — | EP | claimed |
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | claimed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | claimed |
| EP-1395551-B1 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | ELAN PHARM INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166717-A1 | Hydroxy alkyl amines | PSEN1, MAOA, PSEN2 | PDE4D 1243/4885PDE4A 1009/4885PDE4B 971/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | PDE4D 1015/4885PDE4A 872/4885PDE4B 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.